Group 1: Desktop 3D Printing Market - The global desktop 3D printing market is projected to grow from $5.9 billion in 2024 to $20.9 billion by 2030, with a CAGR of 23% [14][11]. - In 2023, China's desktop 3D printing market size was $300 million, accounting for approximately 6% of the global market, with key applications in dental/healthcare (24%), jewelry (21%), and food (19%) [14][12]. - The desktop 3D printing technology is categorized into FDM and SLA, with FDM being more cost-effective but less precise compared to SLA [14][13]. Group 2: Competitive Landscape - Bambu Lab is a leading player in the desktop 3D printing market, achieving revenues of 2.7 billion yuan in 2023, with a projected revenue of 5.5 billion yuan in 2024 [28]. - Creality, established in 2014, has sold over 5.5 million 3D printers globally, maintaining a market share of approximately 39% in the entry-level segment [29]. - Voxelab, founded in 2015, has launched over 20 products and achieved annual revenues exceeding 1 billion yuan, focusing on cost-effective solutions [35]. Group 3: Laser Engraving Market - The global laser engraving market is expected to reach $4.4457 billion in 2024, with a CAGR of 8.7% from 2025 to 2030 [47]. - The desktop laser engraving machine market is growing rapidly, with a 23% increase in sales from 2022 to 2023, reaching 370,000 units sold [47][48]. - Major players in the laser engraving market include xTool, Ortur, and Atomstack, with xTool holding a significant market share [50][54]. Group 4: Key Companies and Financials - Bambu Lab's community forum has over 100,000 members, enhancing user engagement and product adoption [28]. - xTool's revenue exceeded 1 billion yuan in 2023, with projections of 2 to 3 billion yuan in 2024, aiming for over 5 billion yuan by 2025 [54]. - The laser control system supplier, Jin Chengzi, is expected to generate revenue of 212 million yuan in 2024, with a net profit margin of 13.9% [65].

Group 1 - The company announced a share repurchase plan with a total expected amount between 20 million to 30 million RMB [1] - The repurchase period is set from August 28, 2024, to August 27, 2025 [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] Group 2 - As of the latest update, the company has repurchased a total of 1,482,364 shares, representing 0.731% of the total share capital [1] - The total amount spent on repurchased shares is 14,288,602.36 RMB, with a price range of 7.76 RMB to 10.53 RMB per share [1][2] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations [2]

Core Viewpoint - The company, Haizheng Shengcai, announced that it has not repurchased any shares as of July 2025 [1] Summary by Relevant Categories - **Company Announcement** - Haizheng Shengcai released a statement on August 1, indicating that there have been no share repurchases up to July 2025 [1]

格隆汇8月1日丨海正生材(688203.SH)公布，2025年7月，公司未回购股份。截至2025年7月31日，公司 通过上海证券交易所交易系统以集中竞价交易方式已累计回购公司股份1,482,364股，占公司目前总股本 202,678,068股的比例为0.731%，回购成交的最高价为10.53元/股，最低价为7.76元/股，支付的资金总额 为人民币14,288,602.36元（不含印花税、交易佣金等交易费用）。 ...

格隆汇8月1日丨海正生材(688203.SH)公布，2025年7月，公司未回购股份。截至2025年7月31日，公司 通过上海证券交易所交易系统以集中竞价交易方式已累计回购公司股份1,482,364股，占公司目前总股本 202,678,068股的比例为0.731%，回购成交的最高价为10.53元/股，最低价为7.76元/股，支付的资金总额 为人民币14,288,602.36元（不含印花税、交易佣金等交易费用）。 ...

二、回购股份的进展情况 证券代码：688203 证券简称：海正生材 公告编号：2025-43 浙江海正生物材料股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/29 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 月 28 8 月 | 8 | 日~2025 | 年 | 27 | 日 | | 预计回购金额 | 2,000万元~3,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 1,482,364股 | | | | | | | 累计已回购股数占总股本比例 | 0.731% | | | | | | | 累计已回购金额 | 14,2 ...

证券代码：688203 证券简称：海正生材 公告编号：2025-41 浙江海正生物材料股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2025年7月31日 （二）股东会召开的地点：浙江省台州市台州湾新区台州湾大道188号浙江海诺尔生物材料有限公司会 议室 （三）出席会议的普通股股东及其持有表决权数量的情况： ■ 注：截至本次股东会股权登记日，公司总股本为202,678,068股，其中公司回购专用账户的 股份数量为1,482,364股，该等回购的股份不享有表决权，故本次股东会享有表决权的股份总数为 201,195,704股。 （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次会议由公司董事会召集。公司董事长郑柏超先生主持本次股东会。会议采用的表决方式是现场投票 和网络投票相结合的方式。本次会议的召集、召开及表决程序符合《公司法》、《证券法》及《公司章 程》的规 ...

Group 1 - The core viewpoint of the article highlights the recent performance and governance changes of Haizheng Biomaterials, including a slight decline in stock price and a new board member appointment [1] - On July 31, Haizheng Biomaterials closed at 12.12 yuan, down 0.16 yuan, representing a decline of 1.30% from the previous trading day [1] - The trading volume on the same day was 27,331 lots, with a transaction amount of 0.33 billion yuan and a price fluctuation of 2.85% [1] Group 2 - The company operates in the chemical fiber industry, focusing on the research, production, and sales of bio-based materials, which are primarily used in packaging, textiles, and medical fields [1] - In the first quarter of 2025, the company reported revenue of 2.05 million yuan and a net profit of 0.23 million yuan [1] - On July 31, the company announced that the second extraordinary general meeting of 2025 approved the proposal to amend certain corporate governance systems [1] - Additionally, the company reported that director Zhang Jiaying resigned due to personnel adjustments, and Ye Haiyan was elected as the employee representative director [1] - On the same day, the net outflow of main funds was 1.2583 million yuan, accounting for 0.09% of the circulating market value [1]

并出具了法律意见书（法律意见书全文详见上海证券交易所网站 www.sse.com.cn），认为，海正生材本次股东会的召集、召开程序、出席会议人 员的资格、会议提案以及表决方式、表决程序和表决结果，均符合《公司法》《证 券法》《规范运作 1 号指引》等法律、法规、规范性文件和海正生材《公司章程》 的规定，本次股东会通过的决议合法、有效。 特此公告。 | 票数 | | 比例（%） | 票数 | | | 票数 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | （%） | | （%） | | | 普通股 | 120,748,165 | 99.9083 | 107,883 | 0.0892 | 2,885 | 0.0025 | | | 的议案 | | | | | | | | | 审议结果：通过 | | | | | | | | | 表决情况： | | | | | | | | | | 同意 | | | 反对 | | 弃权 | | | 股东类型 | | | | | 比例 | | 比例 | | 票数 | | 比例（%） | | 票数 | | | 票数 ...

杭州市上城区西子国际中心 2 号楼 1501-1503 室 邮编：310020 电话/Tel.:0571-85779929 传真/Fax:0571-85779955 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 北京康达（杭州）律师事务所 BEIJING KANGDA（HANGZHOU）LAW FIRM 北京康达（杭州）律师事务所 关于浙江海正生物材料股份有限公司 法律意见书 康达(杭州)股会字【2025】第 0025 号 二〇二五年七月 北京康达（杭州）律师事务所 海正生材 2025 年第二次临时股东会法律意见书 北京康达（杭州）律师事务所 关于浙江海正生物材料股份有限公司 康达(杭州)股会字【2025】第 0025 号 致：浙江海正生物材料股份有限公司 北京康达（杭州）律师事务所（下称"本所"）接受浙江海正生物材料股份 有限公司（下称"海正生材"或"公司"）委托，指派本所律师出席公司 2025 年 第二次临时股东会（下称"本次股东会"）。根 ...